Thierry Habyarimana1,2,3, Mohammed Attaleb4, Jean Baptiste Mazarati5, Youssef Bakri6, Mohammed El Mzibri4. 1. Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et des Techniques Nucléaires (CNESTEN), Rabat, Morocco. thierryestere@yahoo.fr. 2. Biology of Human Pathologies Laboratory (BioPatH), Faculty of Science and Human Pathologies Center (GenoPatH), Mohammed V University (FSR - Mohammed V University), Rabat, Morocco. thierryestere@yahoo.fr. 3. Biomedical Services Department, Rwanda Biomedical Center (RBC-BIOS), KN 4 Ave, Kigali, Rwanda. thierryestere@yahoo.fr. 4. Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et des Techniques Nucléaires (CNESTEN), Rabat, Morocco. 5. Biomedical Services Department, Rwanda Biomedical Center (RBC-BIOS), KN 4 Ave, Kigali, Rwanda. 6. Biology of Human Pathologies Laboratory (BioPatH), Faculty of Science and Human Pathologies Center (GenoPatH), Mohammed V University (FSR - Mohammed V University), Rabat, Morocco.
Abstract
BACKGROUND: During the last decades, a great interest was given to viral etiology of breast cancer. Indeed, due to recent technical improvements and some encouraging new results, it has been a resurgence of interest in the possibility that a substantial proportion of human breast cancers may be caused by viral infections. High-risk genotypes of human papillomavirus (HPV) have been found in breast cancer cases. In the present study, we aimed to assess the presence of HPV DNA in breast cancer cases from Rwanda and to evaluate the association between HPV infection and clinico-pathological features. METHODS: Therefore, a total of 47 archived formalin-fixed paraffin-embedded biopsies were collected and complete information was recorded. HPV detection and genotyping were done by PCR amplification and DNA sequencing. RESULTS: Overall, HPV DNA was found in 46.81% of cases, HPV16 being the most prevalent subtype (77.27%) followed by HPV33 (13.64%) and HPV31 (9.09%). Comparison of HPV with clinico-pathological features showed no significant difference between HPV infection and breast localization, histological subtype, clinical stage, tumor grade, and intrinsic molecular subtypes. CONCLUSIONS: These findings provide evidence of high prevalence of high-risk HPV in Rwandese patients with breast cancer and suggest that high-risk HPV infections could be a risk factor associated with human breast cancer development.
BACKGROUND: During the last decades, a great interest was given to viral etiology of breast cancer. Indeed, due to recent technical improvements and some encouraging new results, it has been a resurgence of interest in the possibility that a substantial proportion of humanbreast cancers may be caused by viral infections. High-risk genotypes of human papillomavirus (HPV) have been found in breast cancer cases. In the present study, we aimed to assess the presence of HPV DNA in breast cancer cases from Rwanda and to evaluate the association between HPV infection and clinico-pathological features. METHODS: Therefore, a total of 47 archived formalin-fixed paraffin-embedded biopsies were collected and complete information was recorded. HPV detection and genotyping were done by PCR amplification and DNA sequencing. RESULTS: Overall, HPV DNA was found in 46.81% of cases, HPV16 being the most prevalent subtype (77.27%) followed by HPV33 (13.64%) and HPV31 (9.09%). Comparison of HPV with clinico-pathological features showed no significant difference between HPV infection and breast localization, histological subtype, clinical stage, tumor grade, and intrinsic molecular subtypes. CONCLUSIONS: These findings provide evidence of high prevalence of high-risk HPV in Rwandese patients with breast cancer and suggest that high-risk HPV infections could be a risk factor associated with humanbreast cancer development.
Entities:
Keywords:
Breast cancer; DNA; Human papillomavirus; Rwanda
Authors: Endale Gebregzabher; Daniel Seifu; Wondemagegnhu Tigneh; Yonas Bokretsion; Abebe Bekele; Markos Abebe; Gabriella Lillsunde-Larsson; Christina Karlsson; Mats G Karlsson Journal: Int J Breast Cancer Date: 2021-10-11
Authors: Shimaa A Metwally; Maha A Abo-Shadi; Nasra F Abdel Fattah; Ahmed B Barakat; Omar A Rabee; Ahmed M Osman; Amany M Helal; Tarek Hashem; Manar M Moneer; Wassim Chehadeh; Samah A Loutfy Journal: Infect Drug Resist Date: 2021-06-23 Impact factor: 4.003